All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.

  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub
Brought to you by Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

#ASCO23

Share:

Jun 2, 2023

X post image

6 Jun 2023

CONGRESS| #ASCO23 Maureen O'Brien, @ChildrensCBDI discusses AALL1732 phase 3 trial investigating safety outcomes in newly diagnosed patients treated with Inotuzumab ozogamicin for high-risk B-ALL. Further modifications to mitigate toxicity are suggested for future studies #ALLsm

View on 

X post image

6 Jun 2023

CONGRESS | #ASCO23
Ti-Cheng Chang of @StJudeResearch
provides data showing the influence of genetic subtypes, aneuploidy patterns, and secondary genomic alterations on the risk of relapse amongst pediatric pts with SR and/or HR B-ALL with favorable genetics
#ALLsm #leusm

View on 

X post image

6 Jun 2023

CONGRESS| #ASCO23 | Poster
Lyn Balsamo from Yale University presented data showing no difference in physical and emotional function between 4-vs-12 week vincristine/dexamethasone maintenance across different timepoints in children with SR B-ALL.
#allsm #leusm #medicalcongress

View on 

X post image

6 Jun 2023

CONGRESS|#ASCO23 |Poster
Mira Yang presented study associations between mercaptopurine adherence, habit strength, and QOL outcomes in pediatric ALL. Medication adherence was not linked to habit strength but may be associated with QOL outcomes such as physiological stress #ALLsm

View on 

X post image

6 Jun 2023

#ASCO23 | Education session
Jessica Leonard highlighted the prognostic significance, challenges, and controversies in MRD monitoring for the management of ALL. Remaining questions such as the timing/duration of MRD assessments will require multi-center collaborations #ALLsm

View on 

X post image

5 Jun 2023

CONGRESS | #ASCO23 | Shawn Griffin summarized outcomes of hyperCVAD vs pediatric-inspired regimens in ND Hispanic adult pts with B-ALL. Pediatric inspired regimens was associated with worse outcomes:lower 5-yr EFS and OS, and higher relapse rates
#ALLsm #leusm #medicalcongress

View on 

X post image

5 Jun 2023

CONGRESS|#ASCO23|Bijal Shah @MoffittNews presented the 3-yr outcomes of ZUMA-3 by age, prior therapy, and subsequent alloSCT. Brexu-cel showed benefit across all subgroups of adults with R/R B-ALL, though pts with vs w/o prior blina had a lower OS. Further study is needed
#ALLsm

View on 

X post image

3 Jun 2023

CONGRESS | #ASCO23 | Elias Jabbour, @MDAndersonNews shared the updated phase 3 PhALLCON results on ponatinib vs imatinib with low-dose chemo in ND pts with Ph+ALL. Primary endpoint was met: ponatinib yielded higher MRD-neg CR rates; safety profiles were comparable
#ALLsm #leusm

View on 

X post image

2 Jun 2023

CONGRESS| #ASCO23 | @LoriMuffly, @Stanford described treatment settings amongst AYA pts with ND B-ALL and its association on survival. Data showed older AYAs and Hispanics were less likely to receive treatment at SCCs; Treatment at an SCC associated with higher survival #ALLsm

View on 

X post image

2 Jun 2023

CONGRESS | #ASCO23 | Noam Kopmar of @fredhutch presented phase I data on DA-EPOCH plus InO in adult pts with R/R B-ALL. This combination yielded high CR/CRi rates of 84% with an acceptable safety profile, thus representing a promising approach for this patient population
#ALLsm

View on 

X post image

2 Jun 2023

CONGRESS| #ASCO23 | Matthew Wieduwilt presented data on InO induction followed by blina consolidation in older adult pts (≥60 yrs) with ND Ph-neg B-ALL. This chemo-free regimen proved highly effective, and the study met its primary endpoint
#ALLsm #leusm #medicalcongress

View on 

X post image

2 Jun 2023

CONGRESS| #ASCO23| Anthony Stein,@cityofhope reported preliminary results from the first in-human trial evaluating SAR443579 in pts with R/R AML, B-ALL or HR-MDS. Overall, it was well tolerated with no DLTs; CR/CRi was achieved in 18.8% at a dose of ≥ 1000 ug/kg/infusion
#ALLsm

View on 

X post image

2 Jun 2023

CONGRESS| #ASCO23 | @HillLaQuisa from @bcmhouston presents encouraging data demonstrating improved anti-tumor activity of CD5 CAR T-cells manufactured with TKIs in heavily pretreated pts with R/R T-ALL; MRD-negative remissions were achieved with low incidence of severe CRS #allsm

View on 

X post image

2 Jun 2023

CONGRESS | #ASCO23 | Gregory Roloff (@RoloffGreg) of @uchicagoleuk reported real-world outcomes amongst 76 adult pts with R/R B-ALL treated with brexu-cel. High response rates with promising DOR were reported; larger cohorts and longer follow-up are warranted #allsm #leusm

View on 

X post image

2 Jun 2023

CONGRESS | #ASCO23 | Claire Roddie from
@UCL presents topline results from the pivotal FELIX study assessing obe-cel in adult pts with R/R B-ALL. Obe-cel resulted in high CR/CRi rates:76%, very low incidence of Grade ≥3 ICANS and CRS, with ongoing CAR T persistence #allsm #leusm

View on 

X post image

1 Jun 2023

📢 #ASCO23 | 1 day to go!

The @ALL_Hub_ will be attending the 2023 @ASCO Annual Meeting on June 2–6.

Keep an eye out for our post-congress summary articles in #acutelymphoblasticleukemia.

#leusm

View on 

X post image

5 May 2023

Less than 1 month to go!

The @ALL_Hub will be attending the 2023 @ASCO Annual Meeting on June 2–6.

Stay tuned for live coverage and expert opinions.

#ASCO23 #acutelymphoblasticleukemia #IME #ALLhubsm #patientvoice #leusm

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2023American Society of Clinical Oncology

Newsletter

Subscribe to get the best content delivered to your inbox